Sylvie Pollmann
Position: Scientist, Msc, PhD
Phone: +47 22 78 23 16
Email:

TCR lab

Education:

2000 – 2004    PhD in immunology

Institute of Biochemistry, Charité University Hospital, Humboldt-University Berlin,

Germany. “Investigation of the role of the proteasome and PA28 in antigen processing”

 

1996 – 1999    Master of Science in cell biology and human physiology

Blaise Pascal University, Clermont-Ferrand, France

 

1994 – 1996    Technical Diploma in biology and biochemistry

Institute of Technology, Clermont-Ferrand, France

 

 

Research interests/projects:

  • Therapeutic TCR discovery and pre-clinical validation

 

Work experience

 

2017 – present Scientist at the Dept. of Cellular Therapy, OUS-Radiumhospitalet, Oslo.         


2011 – 2016    Scientist at NEXTERA AS, Oslo.


2004 – 2010    Postdoctoral fellow at the Institute of Immunology, Center for Immune Regulation, Rikshospitalet, University of Oslo. “Investigation of rheumatoid arthritis pathogenesis at the cellular level”

 

Publications 2014

Løset GÅ, Berntzen G, Frigstad T, Pollmann S, Gunnarsen KS, Sandlie I (2014)
Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions
Front Oncol, 4, 378
PubMed 25629004

Publications 2012

Nilssen NR, Frigstad T, Pollmann S, Roos N, Bogen B, Sandlie I, Løset GÅ (2012)
DeltaPhage--a novel helper phage for high-valence pIX phagemid display
Nucleic Acids Res, 40 (16), e120
PubMed 22539265

Publications 2011

Pollmann S, Stensland M, Halvorsen EH, Sollid LM, Kvien TK, Fleckenstein B, Molberg O (2011)
Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate
Rheumatol Int, 32 (5), 1271-6
PubMed 21267570

Publications 2009

Stensland ME, Pollmann S, Molberg Ø, Sollid LM, Fleckenstein B (2009)
Primary sequence, together with other factors, influence peptide deimination by peptidylarginine deiminase-4
Biol Chem, 390 (2), 99-107
PubMed 19040354

Publications 2008

Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø (2008)
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents
Ann Rheum Dis, 68 (2), 249-52
PubMed 18723564

Publications 2007

Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Ødegård S, Kvien TK, Molberg Ø (2007)
Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity
Ann Rheum Dis, 67 (3), 414-7
PubMed 18006540

Textoris-Taube K, Henklein P, Pollmann S, Bergann T, Weisshoff H, Seifert U, Drung I, Mügge C, Sijts A, Kloetzel PM, Kuckelkorn U (2007)
The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation
J Biol Chem, 282 (17), 12749-54
PubMed 17308306

Publications 2002

Sijts A, Sun Y, Janek K, Kral S, Paschen A, Schadendorf D, Kloetzel PM (2002)
The role of the proteasome activator PA28 in MHC class I antigen processing
Mol Immunol, 39 (3-4), 165-9
PubMed 12200048

Sun Y, Sijts AJ, Song M, Janek K, Nussbaum AK, Kral S, Schirle M, Stevanovic S, Paschen A, Schild H, Kloetzel PM, Schadendorf D (2002)
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells
Cancer Res, 62 (10), 2875-82
PubMed 12019167

Publications 1999

Salzmann U, Kral S, Braun B, Standera S, Schmidt M, Kloetzel PM, Sijts A (1999)
Mutational analysis of subunit i beta2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes
FEBS Lett, 454 (1-2), 11-5
PubMed 10413086